- Home
- RLAY
as 05-30-2025 4:00pm EST
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 490.3M | IPO Year: | 2020 |
| Target Price: | $18.40 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.77 - $10.72 | Next Earning Date: | 05-05-2025 |
| Revenue: | $7,679,000 | Revenue Growth: | -78.26% |
| Revenue Growth (this year): | -5.08% | Revenue Growth (next year): | 169.23% |
Stock Insider Trading Activity of Relay Therapeutics Inc. (RLAY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bergstrom Donald A | RLAY | President, R&D | Apr 28 '25 | Sell | $3.09 | 31,562 | $95,381.30 | 610,962 | |
| Adams Brian | RLAY | Chief Legal Officer | Apr 28 '25 | Sell | $3.09 | 14,587 | $44,040.48 | 391,385 | |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Apr 28 '25 | Sell | $3.14 | 19,191 | $58,848.64 | 372,858 | |
| Rahmer Peter | RLAY | See remarks | Apr 28 '25 | Sell | $3.09 | 12,103 | $36,540.88 | 400,820 | |
| Patel Sanjiv | RLAY | President and CEO | Apr 23 '25 | Sell | $2.97 | 61,422 | $182,423.34 | 821,667 | |
| Bergstrom Donald A | RLAY | President, R&D | Mar 27 '25 | Sell | $2.84 | 986 | $2,800.24 | 610,962 | |
| Adams Brian | RLAY | Chief Legal Officer | Mar 27 '25 | Sell | $2.84 | 298 | $846.32 | 391,385 | |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Mar 27 '25 | Sell | $2.84 | 4,864 | $13,813.76 | 372,858 | |
| Rahmer Peter | RLAY | See remarks | Mar 27 '25 | Sell | $2.84 | 247 | $701.48 | 400,820 |
Latest Relay Therapeutics Inc. News
RLAY Breaking Stock News: Dive into RLAY Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
Zacks
9 days ago
What Makes Relay Therapeutics (RLAY) a New Buy Stock
Insider Monkey
19 days ago
Relay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy Now
GlobeNewswire
23 days ago
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
Insider Monkey
24 days ago
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory
GlobeNewswire
a month ago
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire
a month ago
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 04/25/2025
Compare RLAY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLAY Relay Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.